Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
5
×
boston blog main
national top stories
biotech
boston
boston top stories
san francisco blog main
enzyme
gene editing
san francisco top stories
agios therapeutics
akili interactive labs
aldehyde
aldeyra therapeutics
allergic conjunctivitis
base editing
biopharma
branden moriarty
broad institute
bruce leuchter
cas13
click therapeutics
clickotine
clinical study
clinical trials
crispr therapeutics
crispr-cas9
data
david benshoof klein
david klein
david liu
deals
digital health
digital medicines
digital therapeutics
disease
dna
drugs
dry eye disease
What
medicine
5
×
therapeutics
5
×
gene
drug
editing
fda
phase
puts
results
aldeyra
announced
approval
backs
beam
benefit
bets
betting
billion
biopharma
cas
click
closer
crispr
data
deal
digital
disclosed
duchenne
editas
editor
example
eye
field
fighting
filing
founders
gain
going
gotten
grabbed
Language
unset
Current search:
therapeutics
×
medicine
×
" national blog main "
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M